Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-JIA after TNFi failure in polyarticular-course juvenile idiopathic arthritis
NL-OMON60279Phase 3Not yet recruiting
- Sponsor
- Duke Clinical Research Institute
- Start
- Jan 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of tofacitinib, adalimumab, etanercept and abatacept in juvenile idiopathic arthritis (JIA) (4 arms), sponsored by Duke Clinical Research Institute. Primary endpoint: Minimal disease activity at Month 6. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NL-OMON60279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60279.